Principal Financial Group Inc. lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1,549.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 772,188 shares of the biopharmaceutical company's stock after acquiring an additional 725,371 shares during the period. Principal Financial Group Inc. owned 0.50% of TG Therapeutics worth $18,061,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently modified their holdings of TGTX. NBC Securities Inc. grew its position in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in TG Therapeutics in the second quarter valued at $35,000. Blue Trust Inc. boosted its position in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth about $53,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in TG Therapeutics during the first quarter worth approximately $58,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
TGTX has been the subject of several analyst reports. B. Riley upped their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. HC Wainwright boosted their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.67.
Check Out Our Latest Report on TGTX
TG Therapeutics Trading Down 4.2 %
NASDAQ TGTX traded down $1.30 during mid-day trading on Friday, reaching $29.54. 3,274,962 shares of the stock were exchanged, compared to its average volume of 3,708,598. The stock has a market capitalization of $4.60 billion, a PE ratio of -295.37 and a beta of 2.19. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 1-year low of $10.98 and a 1-year high of $36.50. The business's fifty day simple moving average is $24.74 and its 200 day simple moving average is $21.07.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The business's revenue for the quarter was down 49.4% compared to the same quarter last year. On average, research analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.
Insider Buying and Selling at TG Therapeutics
In related news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.50% of the stock is owned by company insiders.
TG Therapeutics Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Read More
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
